ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
CinCor Pharma Inc

CinCor Pharma Inc (CINC)

29.06
0.00
(0.00%)
Cerrado 17 Octubre 3:00PM
29.06
0.00
( 0.00% )
Pre Mercado: 7:00PM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
29.06
Postura de Compra
26.58
Postura de Venta
29.48
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
29.06
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

CINC Últimas noticias

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug...

CinCor Pharma to be Acquired by AstraZeneca

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has...

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a...

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:...

CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking...

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in...

CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension

Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential...

CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO...

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00...

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Positive topline Phase 2 BrigHtn data demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SOBRSOBR Safe Inc
US$ 17.51
(120.25%)
434.81k
JDZGJIADE Ltd
US$ 2.83
(66.47%)
6.84M
SABSSAB Biotherapeutics Inc
US$ 3.95
(43.12%)
40
DRTSAlpha Tau Medical Ltd
US$ 3.21
(39.57%)
1
PEGYPineapple Energy Inc
US$ 7.66
(39.02%)
1.4M
ORGSOrgenesis Inc
US$ 1.90
(-41.32%)
6.24k
MTEMMolecular Templates Inc
US$ 0.5841
(-37.19%)
489.79k
NUZENuZee Inc
US$ 1.46
(-36.52%)
1.3M
NKGNNKGen Biotech Inc
US$ 0.466
(-33.43%)
183.86k
PTIXProtagenic Therapeutics Inc
US$ 0.3968
(-26.52%)
71
JTAIJet AI Inc
US$ 0.116
(19.71%)
12.6M
JDZGJIADE Ltd
US$ 2.83
(66.47%)
6.84M
KXINKaixin Holdings
US$ 0.1868
(16.68%)
4.64M
TNONTenon Medical Inc
US$ 4.71
(37.32%)
3.45M
TVGNTevogen Bio Holdings Inc
US$ 1.50
(8.70%)
2.24M
sirant sirant 4 minutos hace
GOOD MORNING EVERYONE 

GO $MCIC 
MCIC
StonkMaster StonkMaster 4 minutos hace
List has been updated, no NWBO, shocker :)

style="font-size: 16px"https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024?utm_medium=email&utm_campaign=govuk-notifications-single-page&utm_source=6ca07490-02f2-467d-ba11-3e542f2b9b18&utm_content=immediately
NWBO
TRUISM TRUISM 5 minutos hace
While it's a plus to be enthusiastic in what one has invested in, I find it prudent to curb ones

expectations; especially when it comes to small cap companies that research and develop

specific technologies, with the goal of eventually bringing their "product to marke
KBLB
tw0122 tw0122 6 minutos hace
$3.10 +40% The aggregate consideration for the transaction is approximately $1,127 million, payable in cash in two installments. The transaction is subject to customary closing conditions and regulatory approvals in Türkiye, with closing expected in the first quarter 2025.

Mikheil Lom
HEPS
Jrod301 Jrod301 7 minutos hace
Could she go Sub-SubPenny? What does David know about Gaming? I guess nothing. FKH
GMER
uranium-pinto-beans uranium-pinto-beans 7 minutos hace
KSPI, HEPS
Kaspi.kz to acquire 65.41% of Hepsiburada for $1.13B
Kaspi.kz (KSPI) has announced that it has signed a definitive agreement with Hanzade Dogan, the founder and controlling shareholder of Hepsiburada (HEPS), and Vuslat Dogan Sabanci, Begum Dogan Faralyali, Arzuhan Dogan Y
floblu14 floblu14 7 minutos hace
Docket last updated: 5 hours ago

Thursday, October 17, 2024
381 misc Stipulation Thu 10/17 2:59 PM
STIPULATION and PROPOSED ORDER regarding the Deposition of Mr. John Wichtowski by Enanta Pharmaceuticals, Inc.. (Fiacco, Barbara)

John Wichtowski
As
ENTA
TrendTrade2016 TrendTrade2016 10 minutos hace
MY EYES ARE BAD WEEKLY SAR NOW HITTING...VSME DID THE SAME THING
VSME
ipo_dude ipo_dude 10 minutos hace
Old news recycled over and over
TNON
NickyCapone NickyCapone 11 minutos hace
Illegal short buying is doomed
AMC
dukeb dukeb 14 minutos hace
Rory and Meltzer's GoFundYourself show seems to be involved with some shady characters. Who could have possibly predicted that?

The most recent GFY episode is a guy who started a company called Fundify that...wait for it...funds startups.

So the original mission of GF
VERB
capgain capgain 14 minutos hace
He was, I watched it last night. I'm not usually up that late, but decided to take a nap yesterday afternoon.
TrendTrade2016 TrendTrade2016 14 minutos hace
HERE COMES THE WEEKLY SAR TEST
JDZG
floblu14 floblu14 14 minutos hace
FWIW -
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares - October 17

On September 30, 2024, Millennium Management LLC, a prominent hedge fund, expanded its investment portfolio by acquiring 73,1295 shares of Enanta Pharmaceuticals Inc (NASDAQ:E
ENTA
ipo_dude ipo_dude 14 minutos hace
Im out
SOBR
ksquared ksquared 16 minutos hace
Howdy, cap. I just got to minute 9:30 and will go back later to watch the whole thing.
It got off to a great start.
Trump was very smart to attend.
floridaboy floridaboy 17 minutos hace
Until Jason files, the onslaught of negativity will continue man. Getting current again is kinda important, too day the least...

It's my opinion that nothing involving Lionsgate/Stars will be shared until 1st quarter of 2025

Patience still required
SAPX
TrendTrade2016 TrendTrade2016 17 minutos hace
LOVE WHEN A CLOWN SAYS THE BEST TRADERS ARE ON THIS STOCK....THE WORST TRADERS ARE ON THIS STOCK...PROVE ME WRONG
RDAR
knrorrel knrorrel 18 minutos hace
$SXTC is too a chinese stock 🥳🥳🥳
Kweb and yinn running! Chinese stock could be explosive today!

imho

SXTC
TrendTrade2016 TrendTrade2016 19 minutos hace
NEXT LESSON OF THE DAY...THIS DILUTED PIG IS JUST THAT...THE OTC STOCK THAT WAS GOING TO MAKE THE OTC GREAT AGAIN...LOL...THE WEEKLY CLOWNS...THE WEEKLY..IF THIS STOCK HAD A TREND IT WOULD BE BASING AT .0017
RDAR
hedge_fun hedge_fun 19 minutos hace
How good of a job is SFRX doing bringing…….

up treasure?

That’s the question isn’t it?

They claim they’re using game changing technology on a (ahem) potential multi-billion dollar wreck site with the industry’s leading recovery process.

I
SFRX
tw0122 tw0122 20 minutos hace
KXIN .1850 + 15% has a heartbeat again sells domestic and imported vehicles in China
KXIN

Su Consulta Reciente

Delayed Upgrade Clock